47.47
전일 마감가:
$47.89
열려 있는:
$47.58
하루 거래량:
2.47M
Relative Volume:
0.95
시가총액:
$115.01B
수익:
$43.23B
순이익/손실:
$6.79B
주가수익비율:
11.85
EPS:
4.0051
순현금흐름:
$9.17B
1주 성능:
-1.37%
1개월 성능:
-0.73%
6개월 성능:
-1.35%
1년 성능:
-3.85%
사노피 ADR Stock (SNY) Company Profile
SNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
SNY
Sanofi Adr
|
47.47 | 116.03B | 43.23B | 6.79B | 9.17B | 4.0051 |
|
LLY
Lilly Eli Co
|
1,032.97 | 960.61B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
219.57 | 526.55B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
216.75 | 392.16B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.97 | 275.53B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
143.15 | 280.45B | 54.45B | 14.42B | 17.15B | 7.333 |
사노피 ADR Stock (SNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-12-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-12-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-09-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-08-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-03-21 | 개시 | Goldman | Neutral |
| 2025-01-30 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-07-26 | 재확인 | Argus | Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-10-30 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-09-06 | 업그레이드 | Berenberg | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-28 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 재개 | Morgan Stanley | Overweight |
| 2022-08-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-08-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-09-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 개시 | Deutsche Bank | Sell |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-03-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-03-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-02-11 | 개시 | SVB Leerink | Mkt Perform |
| 2020-01-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 개시 | Bernstein | Outperform |
| 2019-08-14 | 업그레이드 | UBS | Neutral → Buy |
| 2018-12-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-11-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-03-23 | 업그레이드 | Liberum | Hold → Buy |
| 2018-01-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2017-08-30 | 업그레이드 | HSBC Securities | Reduce → Hold |
모두보기
사노피 ADR 주식(SNY)의 최신 뉴스
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks - Benzinga
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
Sanofi (SNY) Reports Regulatory Win, Barclays Downgrades to 'Equal Weight' with EUR 85 PT - Finviz
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Regeneron Just Moved From Underperform To Buy - Benzinga
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children - Finviz
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Finviz
Where is Sanofi (SNY) Headed According to Wall Street? - Finviz
Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges - Finviz
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Finviz
Total debt per share of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView — Track All Markets
Why Dynavax Stock Soared Today - Finviz
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz
Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy - Sahm
Our Environmental Impact - Sanofi
Bloom Energy Aktie: KI-Boom trifft auf Energiekrise! - Finanztrends
Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades - Finviz
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz
Sanofi (SNY) sees slight pessimism from analysts - MSN
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry ShareholdersThis Is Why (SNY) - Seeking Alpha
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration - Sahm
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks - Sahm
Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025) - ts2.tech
SNY Stock Price and Chart — NASDAQ:SNY - TradingView — Track All Markets
Sanofi (SNY) Sees Slight Pessimism From Analysts - Finviz
JPMorgan Downgrades Sanofi (SNY) to EUR 95 from EUR 105 - Finviz
TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz
Why Wall Street Analysts Are Closely Watching Sanofi (SNY) - Finviz
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Sahm
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Finviz
사노피 ADR (SNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):